Article
Medicine, General & Internal
Yun-Cheng Hsieh, Kuei-Chuan Lee, Chien-Wei Su, Ken-Hsin Lan, Teh-Ia Huo, Yuan-Jen Wang, Hui-Chun Huang, Han-Chieh Lin, Chi-Jen Chu, Yi-Hsiang Huang, Ming-Chih Hou
Summary: The study found that persistent elevation of aminotransferase levels is not uncommon in patients with advanced fibrosis after DAA treatment, and it is associated with impaired baseline liver function and steatosis. Long-term follow-up is needed to assess the impact of liver inflammation on disease progression.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2021)
Review
Immunology
Christine C. Hsu, Harish Gopalakrishna, Maria Mironova, Mei-Hsuan Lee, Chien-Jen Chen, Hwai- Yang, Manfred Wiese, Kyong-Mi Chang, Elizabeth C. Wright, Tomilowo Abijo, Jordan J. Feld, David E. Kaplan
Summary: In a hepatitis C virus (HCV)-controlled human infection model (CHIM), researchers assessed the risk of hepatocellular carcinoma (HCC) after viral clearance in noncirrhosis patients with sustained virological response (SVR) to HCV treatment. The overall HCC rate in noncirrhosis SVR patients was 0.33 per 100 patient-years. The data suggests that the risk of HCC in the HCV CHIM is very low or negligible.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Gastroenterology & Hepatology
Teresa Broquetas, Paula Herruzo-Pino, Zoe Marino, Dolores Naranjo, Mercedes Vergara, Rosa M. Morillas, Xavier Forns, Jose A. Carrion
Summary: Cirrhosis is present in more than half of HCV-cACLD patients 3 years after SVR, despite the normalization of liver function parameters, serological non-invasive tests, and TE values. The low diagnostic accuracy of non-invasive methods after SVR highlights the necessity of long-term surveillance.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Shereen Abdel Alem, Rasha Eletreby, Zeinab Abdellatif, Ahmed Ramadan, Ahmed Nagy, Mohamed AbdAllah, Aisha Elsharkawy, Rabab Fouad, Gamal Esmat, Omnia Tantawi
Summary: This 3-year follow-up study demonstrates the durability of SVR, improvement of liver function parameters and ALBI score and grade in patients with an advanced stage of fibrosis after successful treatment with DAAs. Patients with advanced fibrosis and cirrhosis showed a more pronounced improvement in liver stiffness during follow-up.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Medicine, Research & Experimental
Aline Marcia Marques Braz, Fernanda Cristina Winckler, Larissa Sarri Binelli, Luis Guilherme Chimeno, Lia Beatriz Mantovani Lopes, Rodrigo Santos Lima, Rafael Plana Simoes, Rejane Maria Tommasini Grotto, Marjorie de Assis Golim, Giovanni Faria Silva
Summary: In cirrhotic patients with chronic hepatitis C, the most important biomarkers for predicting regression are TCD4+ lymphocytes. Non-regressors (NR) have lower levels of liver stiffness since baseline compared to regressors (R), while NK cells are increased in NR. The differences in the profile of circulating immune cells between R and NR allow for the development of a predictive model for regression of liver stiffness after SVR, although further validation in larger patient cohorts is needed.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Maria Sanchez-Azofra, Inmaculada Fernandez, Maria L. Garcia-Buey, Lourdes Dominguez-Dominguez, Conrado M. Fernandez-Rodriguez, Antonio Mancebo, Lucia Bonet, Pablo Ryan, Francisco Gea, Antonio Diaz-Sanchez, Marian Garcia-Mayor, Luz Martin-Carbonero, Pilar Castillo, Maria L. Manzano, Leticia Gonzalez-Moreno, Federico Pulido, Maria L. Gutierrez, Jose M. Moreno, Irene M. Garcia-Amengual, Guillermo Cuevas, Antonio Guerrero, Miguel Rivero-Fernandez, Maria E. Portales, Maria L. Montes, Antonio Olveira
Summary: Among patients with chronic hepatitis C and stage 3 fibrosis, the risk of developing primary liver tumors after sustained virological response is low, except for males older than 55 years, who have a significantly higher risk.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie-Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis
Summary: The study showed that it is safe to discontinue nucleos(t)ide analogues therapy in non-cirrhotic patients with HBeAg-negative chronic hepatitis B. Over a median follow-up of more than 5 years, half of the patients remained without retreatment, with a substantial proportion achieving functional cure.
LIVER INTERNATIONAL
(2021)
Article
Oncology
Chiara Rocha, Erin H. Doyle, Chip A. Bowman, M-Isabel Fiel, Ashley E. Stueck, Nicolas Goossens, Kian Bichoupan, James F. Crismale, Jasnit Makkar, Sara Lewis, Ponni V. Perumalswami, Thomas D. Schiano, Yujin Hoshida, Myron Schwartz, Andrea D. Branch, Neal Patel
Summary: Successful treatment of hepatitis C reduces liver inflammation and fibrosis, but patients are still at risk of developing hepatocellular carcinoma. Risk factors for post-SVR HCC include non-Caucasian race, smoking, age over 60, low albumin level, elevated AST/ALT ratio, and low platelet count. AFP may be a promising marker for post-SVR HCC risk.
Article
Gastroenterology & Hepatology
Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, Wenyu Lin, Raymond T. Chung
Summary: The HCV recurrence risk after achieving SVR with all-oral DAAs therapy is low, and the risk of HCV recurrence in high-risk and HIV/HCV-coinfected populations was driven by an increase in reinfection rather than late relapse.
LIVER INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Sung Yong Han, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Sung Ik Pyeon, Young Joo Park, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
Summary: The study found that SOF/RBV treatment was effective and safe in Korean patients with HCV GT2 infection. Factors such as RVR and no previous history of HCC were positive predictors of SVR12.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Batbold Batsaikhan, Ching-I. Huang, Ming-Lun Yeh, Chung-Feng Huang, Yi-Hung Lin, Po-Cheng Liang, Ming-Yen Hsieh, Yi-Ching Lin, Jee-Fu Huang, Wan-Long Chuang, Jin-Ching Lee, Ming-Lung Yu, Hsing-Tao Kuo, Chia-Yen Dai
Summary: This study found that the prevalence of persistent cryoglobulinemia is 34.5% after completing antiviral therapy. Persistent cryoglobulinemia is associated with advanced fibrosis and HCV clearance.
Article
Immunology
Anais Corma-Gomez, Juan Macias, Francisco Tellez, Luis Morano, Antonio Rivero, Miriam Serrano, Maria Jose Rios, Francisco Jesus Vera-Mendez, Marta Santos, Luis Miguel Real, Rosario Palacios, Ignacio de Los Santos, Paloma Geijo, Arkaitz Imaz, Dolores Merino, Maria Jose Galindo, Sergio Reus-Banuls, Miguel Angel Lopez-Ruz, Carlos Galera, Juan A. Pineda
Summary: The study found that the majority of HCV-infected patients develop liver complications within 3 years after achieving sustained virological response, with hepatic encephalopathy and ascites not usually emerging after this period. On the other hand, hepatocellular carcinoma and portal hypertension gastrointestinal bleeding may occur in the longer term.
Article
Gastroenterology & Hepatology
Kazuhito Kawata, Masanori Atsukawa, Kazuyoshi Ohta, Takeshi Chida, Hidenao Noritake, Taeang Arai, Katsuhiko Iwakiri, Satoshi Yasuda, Hidenori Toyoda, Tomomi Okubo, Atsushi Hiraoka, Tsunamasa Watanabe, Haruki Uojima, Akito Nozaki, Joji Tani, Asahiro Morishita, Fujito Kageyama, Yuzo Sasada, Masamichi Nagasawa, Masahiro Matsushita, Tatsuki Oyaizu, Shigeru Mikami, Tadashi Ikegami, Hiroshi Abe, Kentaro Matsuura, Yasuhito Tanaka, Akihito Tsubota
Summary: This study aimed to investigate the incidence, survival probability, and factors associated with non-HCC malignancies in patients with chronic HCV infection after achieving SVR. The measurement of M2BPGi at baseline and SVR12 may help predict the occurrence of non-HCC malignancies after SVR.
HEPATOLOGY COMMUNICATIONS
(2022)
Article
Gastroenterology & Hepatology
Georg Semmler, Elias Laurin Meyer, Karin Kozbial, Philipp Schwabl, Stefanie Hametner-Schreil, Alberto Zanetto, David Bauer, David Chromy, Benedikt Simbrunner, Bernhard Scheiner, Albert F. Stattermayer, Matthias Pinter, Rainer Schofl, Francesco Paolo Russo, Helena Greenfield, Michael Schwarz, Caroline Schwarz, Michael Gschwantler, Sonia Alonso Lopez, Maria Luisa Manzano, Adriana Ahumada, Rafael Banares, Monica Pons, Sergio Rodriguez-Tajes, Joan Genesca, Sabela Lens, Michael Trauner, Peter Ferenci, Thomas Reiberger, Mattias Mandorfer
Summary: The study developed risk stratification algorithms for de novo HCC development after SVR in patients with ACLD. Parameters such as post-treatment AFP, alcohol consumption, age, LSM, and albumin accurately predicted de novo HCC development and stratified patients into low- and high-risk groups. These algorithms identified approximately two-thirds of patients with cACLD as having a low risk of <1%/year for HCC development, showing effectiveness in risk assessment and surveillance.
JOURNAL OF HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Chih-Hsuan Luan, Pin-Shuo Su, Chi-Jen Chu, Chung-Chi Lin, Chien-Wei Su, Shou-Dong Lee, Yuan-Jen Wang, Fa-Yauh Lee, Yi-Hsiang Huang, Ming-Chih Hou
Summary: After achieving sustained virological response (SVR) through oral direct-acting anti-virals (DAAs), patients with chronic hepatitis C (CHC) still face a residual risk of hepatocellular carcinoma (HCC). Variables independently associated with de novo HCC include advanced liver fibrosis, high levels of alpha-fetoprotein (AFP) and albumin-bilirubin (ALBI) grade at the end of treatment, and high body mass index (BMI).
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2023)
Article
Gastroenterology & Hepatology
Raymond T. Chung, Wendy C. King, Marc G. Ghany, Mauricio Lisker-Melman, Amanda S. Hinerman, Mandana Khalili, Mark Sulkowski, Mamta K. Jain, Eun-Young K. Choi, Michael A. Nalesnik, Atul K. Bhan, Gavin Cloherty, David K. Wong, Richard K. Sterling
Summary: This study evaluated the role of HBV RNA and HBcrAg in characterizing HBV-HIV coinfection and found that the use of novel HBV markers can continue to improve the suppression of HBV transcription and translation in suppressive dually active antiviral therapy. However, for HBeAg patients, the benefit of combination antiviral therapy is limited.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Norah A. Terrault, Abdus S. Wahed, Jordan J. Feld, Stewart L. Cooper, Mark G. Ghany, Mauricio Lisker-Melman, Robert Perrillo, Richard K. Sterling, Mandana Khalili, Raymond T. Chung, Philip Rosenthal, Robert J. Fontana, Arif Sarowar, Daryl T. Y. Lau, Junyao Wang, Anna S. Lok, Harry L. A. Janssen
Summary: This study developed and validated a prediction model for HBsAg loss in HBeAg-negative chronic hepatitis B patients over a 3-year horizon. Factors associated with increased HBsAg loss included older age, race, HBV genotype, and HBV-DNA levels. The HBRN SQuARe score accurately predicted HBsAg loss and can be useful in patient care and counseling.
Letter
Gastroenterology & Hepatology
Marc G. Ghany, Wendy C. King, Mauricio Lisker-Melman, Anna S. F. Lok, Norah Terrault, Harry L. A. Janssen, Mandana Khalili, Raymond T. Chung, William M. Lee, Daryl T. Y. Lau, Gavin A. Cloherty, Richard K. Sterling
Article
Infectious Diseases
Andinet Gizaw, Wendy C. King, Amanda S. Hinerman, Raymond T. Chung, Mauricio Lisker-Melman, Marc G. Ghany, Mandana Khalili, Mamta K. Jain, Jacob Graham, Theresa Swift-Scanlan, David E. Kleiner, Mark Sulkowski, David K. Wong, Richard K. Sterling
Summary: This study suggests that TDF use in HBV-HIV co-infected adults can lead to worsening renal function and bone turnover.
Article
Immunology
Yevgeniy Yuzefpolskiy, Peter Morawski, Mitch Fahning, Cate Speake, Sandra Lord, Anu Chaudhary, Chihiro Morishima, Mark H. Wener, Mariko Kita, Lucas McCarthy, Jane H. Buckner, Daniel J. Campbell, Estelle Bettelli
Summary: This study found that MS patients treated with different modifying therapies have varied immune responses to SARS-CoV-2 vaccines. B cell depletion and fingolimod therapy significantly reduced S-specific antibody response, and fingolimod therapy also compromised CD4 and CD8 T cell responses.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Mauricio Lisker-Melman, Abdus S. Wahed, Marc G. Ghany, Raymond T. Chung, Wendy C. King, David E. Kleiner, Atul K. Bhan, Mandana Khalili, Mamta K. Jain, Mark Sulkowski, David K. Wong, Gavin Cloherty, Richard K. Sterling
Summary: In patients coinfected with HBV and HIV, HBV RNA and HBcrAg can still be detected despite viral suppression, and their levels are associated with the extent of HBsAg and HBcAg staining in liver cells. This suggests that residual transcription and translation may contribute to liver pathology even when viral replication is suppressed.
Review
Gastroenterology & Hepatology
David Yardeni, Kyong-Mi Chang, Marc G. Ghany
Summary: Hepatitis B virus is a major cause of cirrhosis and hepatocellular carcinoma, and despite the availability of an effective vaccine, chronic infection continues to be prevalent. Current therapies are effective at suppressing the virus during treatment, but do not provide long-term viral suppression. There is a need for novel therapies that can achieve functional or complete cure by targeting key components of the virus. This review discusses current best practices for managing chronic HBV infection and new emerging therapies with the potential for a cure.
Article
Gastroenterology & Hepatology
Nehna Abdul Majeed, Ahmad Samer Alawad, Kin Seng Liem, Varun Takyar, Harvey Alter, Jordan J. Feld, Harry L. A. Janssen, Marc G. Ghany
Summary: This study evaluated the rate of hepatitis B virus (HBV) reactivation in patients with chronic hepatitis C (CHC) during direct acting antiviral (DAA) therapy. The risk of HBV reactivation was found to be low, and testing for HBV DNA is recommended only in patients with ALT flares or failure of ALT normalization during DAA treatment.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Herbert L. Bonkovsky, Sean P. Rudnick, Christopher D. D. Ma, Jessica R. Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, Karli Hedstrom, Hetanshi Naik, Akshata Moghe, Karl E. Anderson
Summary: Ledipasvir/sofosbuvir is effective for treating both chronic hepatitis C (CHC) and porphyria cutanea tarda (PCT) without the need for additional treatment methods.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Marc G. Ghany, Wendy C. King, Amanda S. Hinerman, Anna SF. Lok, Mauricio Lisker-Melman, Raymond T. Chung, Norah Terrault, Harry L. A. Janssen, Mandana Khalili, William M. Lee, Daryl T. Y. Lau, Gavin A. Cloherty, Richard K. Sterling
Summary: This study examined the predictive ability of HBV RNA and HBcrAg for patients with chronic hepatitis B (CHB) and found that they could predict key events such as not sustained inactive carrier phase, ALT flare, HBeAg loss, and HBsAg loss. However, their addition to readily available markers provided only small improvements in predictive ability.
Article
Gastroenterology & Hepatology
Marc G. Ghany, Maria Buti, Pietro Lampertico, Hannah M. Lee
Summary: Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) in June 2022 to achieve consensus on chronic HBV and HDV treatment endpoints. The conference focused on the primary goal of guiding clinical trials aiming to cure HBV and HDV, and reached agreements on key points such as preferred endpoints for trials, suitable patient candidates, and the role of novel biomarkers and existing therapies.
Article
Medicine, Research & Experimental
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, Mark H. Wener, Yevgeniy Yuzefpolskiy, Estelle Bettelli, Jane H. Buckner, Cate Speake, Marion Pepper, Daniel J. Campbell
Summary: This study analyzed blood samples from patients with rheumatoid arthritis (RA) after receiving a 2-dose mRNA COVID-19 vaccine. The findings showed that patients on the cytotoxic T lymphocyte antigen 4-Ig therapy had reduced levels of SARS-CoV-2-neutralizing antibodies after vaccination. Additionally, these patients had decreased activation and class switching of SARS-CoV-2-specific B cells, as well as impaired production of helper cytokines by SARS-CoV-2-specific CD4+ T cells. The study provides valuable insights into the impaired response to SARS-CoV-2 vaccination in RA patients on different immune-modifying therapies.
Article
Gastroenterology & Hepatology
Lei Yu, Sarim Yousuf, Shahrukh Yousuf, Jeffrey Yeh, Scott W. Biggins, Chihiro Morishima, Irene Shyu, Galen O'Shea-Stone, Brian Eilers, Annie Waldum, Valerie Copie, Jason Burkhead
Summary: This study found that copper deficiency is relatively common in patients with advanced cirrhosis and is associated with an increased risk of infection, a distinctive metabolic profile, and an increased risk of death before transplantation.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
David J. Kuter, Herbert L. Bonkovsky, Susana Monroy, Gayle Ross, Encarna Guillen-Navarro, Maria Domenica Cappellini, Anna-Elisabeth Minder, Ole Hother-Nielsen, Paolo Ventura, Gang Jia, Marianne T. Sweetser, Manish Thapar
Summary: Long-term monthly givosiran treatment provides sustained improvement in clinical manifestations of acute hepatic porphyria (AHP) with a positive risk/benefit profile.
JOURNAL OF HEPATOLOGY
(2023)
Article
Pathology
Rebecca S. Treger, Patrick C. Mathias, Andrew J. Cowan, Damian Green, Kathleen Hutchinson, Andrew Bryan, Anu Chaudhary, Susan L. Fink, Mark H. Wener, Chihiro Morishima
Summary: Our study evaluates the real-world performance and reference intervals of the Binding Site Freelite serum free light chain (SFLC) assay and highlights the impact of assay drift and other potential factors on the kappa/lambda ratio (KLR) distribution. We propose a revised reference interval for KLR that improves assay interpretation and should prompt the reconsideration of Freelite reference intervals worldwide.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)